Njk Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 0.21 M
as on 17-11-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
as on 17-11-2024
- Revenue 26.25%
(FY 2023)
- Profit 4.44%
(FY 2023)
- Ebitda 18.53%
(FY 2023)
- Net Worth 29.82%
(FY 2023)
- Total Assets 9.92%
(FY 2023)
About Njk Pharmacy
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.21 M.
The company currently has active open charges totaling ₹1.00 Cr.
Narayanasamy Elamaran, Ezhilmaran, and Ranganathan Manimaran serve as directors at the Company.
- CIN/LLPIN
U24299TN2018PTC125785
- Company No.
125785
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Njk Pharmacy?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayanasamy Elamaran  | Director | 12-May-2021 | Current |
| Ezhilmaran | Director | 12-May-2021 | Current |
| Ranganathan Manimaran | Director | 15-Feb-2022 | Current |
Financial Performance and Corporate Structure Insights of Njk Pharmacy.
Njk Pharmacy Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.25% increase. The company also saw a slight improvement in profitability, with a 4.44% increase in profit. The company's net worth Soared by an impressive increase of 29.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Njk Pharmacy?
In 2023, Njk Pharmacy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Panyam Cements And Mineral Industrties LimitedActive 69 years 6 monthsNarayanasamy Elamaran is a mutual person
- New Delta Gear Manufacturers Private LimitedActive 28 years 6 months
Narayanasamy Elamaran is a mutual person
- Antares Constructions And Developers Private LimitedActive 3 years 6 months
Narayanasamy Elamaran and Ranganathan Manimaran are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 11 Jun 2021 | ₹1.00 Cr | Open |
How Many Employees Work at Njk Pharmacy?
Unlock and access historical data on people associated with Njk Pharmacy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Njk Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Njk Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
